

SOUTH-EAST ASIA REGION

EPI FACTSHEET 2024



World Health
Organization

REGIONAL OFFICE FOR

South-East Asia



©WHO / Payden



South-East Asia Region EPI July 2024



WHO South-East Asia Region

The Immunization and Vaccine Development (IVD) unit of the Department of Communicable Diseases of the World Health Organization (WHO), Regional Office for South-East Asia (SEARO), has been producing the Expanded Programme on Immunization (EPI) factsheets for all Member States of the South-East Asia (SEA) Region and the Region annually. The primary data sources of the EPI factsheet are the WHO-UNICEF Joint Reporting Form (JRF) and the SEA Region annual EPI reporting form (AERF), in which each country officially reports EPI and vaccine preventable diseases related core information annually. The EPI factsheets 2024 are based on 2023 data reported to WHO SEARO by Member States.

[Click to explore the country fact sheet](#)



Bangladesh



Bhutan



DPR Korea



India



Indonesia



Maldives



Myanmar



Nepal




Sri Lanka



Thailand



Timor Leste




Disclaimer for all maps:

The boundaries and names shown and the designations used on all the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, of concerning the delimitation of its frontiers or boundaries.



Regional demographic attributes

SEA regional population density by first administrative level.



Basic information by country, 2023

Country	2023 population ¹					Mortality ²				Administrative levels	
	Total population	Live births	Under 1 year	Under 5 years	Under 15 years	Neonatal mortality rate (per 1000 LB)	Infant mortality rate (per 1000 LB)	Under-5 mortality rate (per 1000 LB)	Maternal mortality ratio (per 100 000 LB)	Number of province /region / division	Number of district
Bangladesh	171,000,730	3,360,164	3,269,440	17,476,275	49,214,010	17.36	24.07	28.78	123	8	64
Bhutan	727,145	9,847	9,847	59,666	179,313	12.95	20.1	23.7	59.95	0	20
DPR Korea	25,404,298	305,384	302,551	1,537,059	4,901,666	9.2	13.57	17.0	106.7	13	210
India	1,392,330,000	19,866,112	26,576,295			18.1	25.5	29.06	102.7	36	757
Indonesia	277,432,360	4,461,112	4,370,837	21,844,973	65,805,113	10.75	18.13	21.26	172.9	38	514 ^a
Maldives	590,297	5,881	5,827	38,989	113,019	3.7	4.77	5.58	56.69	1	21
Myanmar	55,122,801	964,649	937,088	4,442,414	12,718,387	21.05	32.49	40.09	178.7	17	330 ^b
Nepal	29,682,029	509,308	515,533	2,596,686	7,859,011	17	22.96	27.34	174.4	7	77
Sri Lanka	22,037,000	247,900	246,512	1,893,000	5,568,000	3.7	5.6	6.5	29	9	26
Thailand	66,052,615	517,934	510,459	2,758,022	10,324,273	4.45	6.96	8.13	28.6	77	928
Timor-Leste	1,336,222	33,260	31,832	125,492	522,943	21.73	41.52	48.58	203.9	no data	14
SEAR	2,041,715,497	30,281,551	36,776,221	52,772,576	157,205,735	16.6	23.9	27.6	116.76	-	-

¹ SEA Region annual EPI reporting form, 2023

^a District & city

^b Township

² WHO, Global Health Observatory (GHO) data <http://apps.who.int/gho/data> accessed on 02 July 2024

Routine immunization systems and services are strengthened

Routine immunization schedules by country, 2023

Country	BCG	DTP	Hib	HepB	MCV/MRCV	OPV/IPV	TT/Td	Vitamin A	Other vaccinations
Bangladesh	At birth	DTPHibHepB - 6W, 10W, 14W			MR- 38W, 15M	6W, 10W, 14W IPV (flPV)-6W, 14W	Td- Females 15Y to 49Y (5 doses with an interval of + 1 month, + 6 months, + 1 year and + 1 year with preceding dose)	6-59M	PCV- 6W, 10W, 14W
Bhutan	At birth	HepB- At birth (within 24 hours) DTPHibHepB- 6W, 10W, 14W DTP- 24M			MMR- 9M, 24M	At birth, 6W, 10W, 14W IPV-14W, 32W	Td- 6Y, 12Y and during pregnancy (at first contact and one month later)	6M, 12M, 18M, 24M, 30M, 36M, 42M, 48M and 54M	HPV- Females 12 years and grade VI girls (two doses 6 months apart) HPV for boys PCV- 6W, 10W, 9M
DPR Korea	At birth	HepB- At birth DTPHibHepB - 6W, 10W, 14W			MR-9M, 15M	6W, 10W, 14W IPV-14W	Td - 3M, 4M of pregnancy	6-59M	-
India	0-1 year	HepB - At birth DTPHibHepB - 6W, 10W, 14W DTP - 16-24M, 5-6Y			MR- 9-12M, 16-24M	At birth, 6W, 10W, 14W, 16-24M IPV (flPV)-6W, 14W, 9M	Td- 10Y and 16Y, 2 doses/booster for pregnant women	9M, 18M, 24M, 30M, 36M and 42M	JE vaccine- 9-12M and 16-24M (select JE endemic districts) PCV - 6W, 14W, 9M Rotavirus-6W,10W,14W
Indonesia	At birth, 0-1M	HepB- 0-24 hours of birth DTPHibHepB - 2M, 3M, 4M, 18M			MR-9M, 18M, 7Y	0-1M, 2M, 3M, 4M IPV- 4M, 9M	DT - 6-7Y Td- 8Y, 11Y, 15-39Y (child bearing women)	6-59M	HPV- 11Y (national), 12Y (132 districts) JE_LiveAtd - 10M (Bali & West Kalimantan province) PCV- 2M,3M,12M Rotavirus - 2M, 3M, 4M
Maldives	At birth	HepB-At birth DTPHibHepB - 2M, 4M, 6M DTP booster- 4 years			MR-9M MMR - 18M	2M, 4M, 6M, pilgrims to Haj & Umrah and travellers to polio endemic countries IPV-6M	Td - Females of child bearing age (15-49 years) - +1M, +6M, +1Y, +1Y	9M, 18M, 24M, 30M, 36M, 42M, 48M, 54M, 60M	Men ACWY-135 conj- all travellers to Haj & Umrah YF- >9M travellers to endemic countries HPV- 10 years (2 doses 6M apart) cholera - >2 years travellers to endemic countries
Myanmar	Birth to 2M	HepB- At birth DTPHibHepB- 2M, 4M, 6M, 18M			MR- 9M, 18M	2M, 4M, 6M IPV- 4M	Td-First contact during pregnancy and 4 weeks later	6-59M	PCV- 2M, 4M, 6M; HPV-9Y girls JE_LiveAtd - 9M ; Rotavirus-2M, 4M
Nepal	At birth	DTPHibHepB - 6W, 10W, 14W			MR-9M, 15M	6W, 10W, 14W flPV-14W, 9M	Td- First contact pregnancy, +1M, 1 dose each in subsequent pregnancy	6M-5Y, +6M	JE_LiveAtd - 12M PCV- 6W, 10W, 9M Rotavirus- 6W,10W Typhoid conjugate vaccine - 15M
Sri Lanka	At birth	DTPHibHepB - 2M, 4M, 6M DTP - 18M			MMR - 9M, 3Y	2M, 4M, 6M, 18M, 5Y IPV (flPV)- 2M, 4M	DT - 5Y aTd - 12Y (grade 7) TT - Pregnant women (2 doses in 1st pregnancy and 1 dose in subsequent 3 pregnancies)	6-59M	JE_LiveAtd - 1Y; YF - travellers to yellow fever endemic countries; HPV- Girls grade VI at school, on 10Y completion, 2 doses 6M apart; Typhoid fever polysaccharid vaccine - high risk categories, food handlers, based on transmission pattern and data
Thailand	At birth	HepB - At birth, 1M (new-born from HepB carrier mother) Adult HepB - Healthcare Workers (1st contact +6M) DTPHibHepB - 2M, 4M, 6M DTP - 1.5Y, 4Y			MMR - 9M, 1.5Y MR - Healthcare workers, all university students of first year and faculty of medical and public health	6M, 1.5Y, 4Y IPV-2M, 4M	Td- 12Y (grade 6), Adult (20Y+ booster dose every 10 years), Pregnant women 1st contact, +1M, +6M (depending on vaccination history)	-	JE_LiveAtd- 1Y, 2.5Y Rotavirus- 2M, 4M, 6M HPV- females at grade V (2 doses 6M apart) Men ACWY-135 _conj - 9 months to 55 years (two doses five years apart), travellers (if >55 years, they should be certified by their physician) YF - >=9 monts old travellers
Timor-Leste	At Birth	HepB- At birth, 24 hours till two weeks DTPHibHepB- 6W, 10W, 14W DTP-18M; DT-6Y			MR-9M, 18M	Birth, 6W, 10W, 14W IPV-14W	Td-Females 15Y-49Y (1st pregnancy contact, +1M, +6M, +1Y, +1Y)	6-59M (6M interval)	Rotavirus-6W,10W,14W; PCV- 6W,10W,14W

Source: WHO/UNICEF JRF, 2023



W=Week

M=Month

Y=Year



Immunization coverage by antigen, 2009-2023




Source: WHO and UNICEF estimates of immunization coverage

Immunization coverage by country, 2020-2023


Country	BCG				HepB birth dose				DTP3				MCV1/MRCV1				MCV2/MRCV2			
	2020	2021	2022	2023	2020	2021	2022	2023	2020	2021	2022	2023	2020	2021	2022	2023	2020	2021	2022	2023
Bangladesh	99	99	99	99	no birth dose				98	98	98	98	97	97	97	97	93	93	93	93
Bhutan	98	99	99	97	85	84	94	94	95	98	98	99	93	97	97	99	92	91	97	97
DPR Korea	99	95	99	63	99	99	50	0	97	41	0	16	99	99	67	28	99	91	0	16
India	85	84	91	89	54	55	63	63	85	85	93	91	89	89	95	93	81	82	90	90
Indonesia	87	81	93	88	73	70	85	88	77	67	91	83	76	72	92	82	60	53	71	62
Maldives	99	99	99	99	99	99	99	99	99	96	99	99	98	97	98	99	97	98	98	99
Myanmar	87	48	79	80	21	6	8	17	84	37	71	76	91	44	75	74	90	42	64	65
Nepal	92	95	96	97	no birth dose				84	91	90	94	87	90	90	93	74	87	87	89
Sri Lanka	99	99	99	99	no birth dose				96	96	98	99	96	97	99	99	96	97	98	99
Thailand	99	99	99	99	93	89	89	89	97	92	92	92	96	93	93	93	87	87	87	87
Timor-Leste	92	90	90	90	64	76	76	76	83	83	83	83	74	72	72	72	72	72	72	72
SEA Region	87	85	92	90	50	50	57	57	86	83	92	90	88	87	94	91	80	79	86	85

Source: WHO and UNICEF estimates of immunization coverage

DTP3 immunization coverage by first administrative level*, 2023




* Bhutan, Maldives and Timor-Leste by country
Source: SEA Region annual EPI reporting form, 2023



Source: DTP coverage from WHO and UNICEF estimates and UN estimated under 1 year population



Range of protection increased through addition of vaccines




Planning and management indicators by country, 2023

Country	cMYP for immunization	NTAGI	Spending on vaccines by the government	Spending on routine immunization programme by the government	Updated micro-plans that include activities to improve immunization coverage	Most recent EPI CES
Bangladesh	2023-2027	fully functional	17.5%	20.9%	64 districts (100%)	2023
Bhutan	2019-2023	fully functional	64.3%	73.0%	no data	2023
DPR Korea	2020-2024	fully functional	no data	no data	210 districts (100%)	National Immunization Coverage Survey 2017
India	2023-2027	fully functional	94.6%	96.3%	757 districts (100%)	National Family Health Survey-5 2021
Indonesia	2020-2024	fully functional	95%	89.6%	no data	DHS - 2023
Maldives	2020-2024	fully functional	100%	100%	no data	Demographic Health Survey 2017
Myanmar	2017 -2021	fully functional	33.8%	no data	314 districts (95%)	Vaccination Coverage Evaluation Survey 2019-20
Nepal	2023-2030	fully functional	27.6%	48%	77 districts (100%)	Nepal, Demographic Health Survey 2022
Sri Lanka	2017-2022	fully functional	47.4%	no data*	26 districts (100%)	EPI coverage survey Puttalam district 2017
Thailand	2022-2027	fully functional	100%	no data	928 districts (100%)	CES for routine and school-based immunization 2018
Timor-Leste	2016-2023	fully functional	80%	73%	14 districts (100%)	EPI coverage evaluation survey 2023

Source: WHO/UNICEF JRF, 2023

* Integrated health systems provide all operational costs

DTP3 coverage, diphtheria and pertussis cases, 2000-2023



Source: WHO and UNICEF coverage estimates; WHO/UNICEF JRF and EPI/MoHFW; Diphtheria and pertussis cases from JRF 2000-2023

Vaccine preventable diseases reported by country, 2021-2023

Country	2021							
	Polio	Diphtheria	Pertussis	Total tetanus (NT)	Measles	Rubella	Mumps	JE
Bangladesh	0	0	0	33 (33)	203	129	ND	82
Bhutan	0	0	ND	0 (0)	ND	0	0	0
DPR Korea	0	ND	ND	ND (ND)	0	0	ND	ND
India	0	1,768	593	1,240 (81)	5,916	1,683	758	489
Indonesia	0	235	ND	ND (11)	394	268	ND	13
Maldives	0	0	0	0 (0)	0	0	0	0
Myanmar	0	3	ND	ND (8)	8	3	ND	2
Nepal	0	29	4,588	927 (2)	143	44	13,075	31
Sri Lanka	0	0	0	4 (0)	0	0	73	4
Thailand	0	0	4	0 (0)	242	8	560	0
Timor-Leste	0	0	0	ND (ND)	3	4	0	ND
SEAR	0	2,035	5,185	2,204 (135)	6,909	2,139	14,466	621

Country	2022							
	Polio	Diphtheria	Pertussis	Total tetanus (NT)	Measles	Rubella	Mumps	JE
Bangladesh	0	6	0	21 (21)	311	236	ND	110
Bhutan	0	0	0	0 (0)	7	4	ND	0
DPR Korea	0	0	0	0 (0)	0	0	0	0
India	0	3,286	4,362	65 (65)	43,491	2,561	6	1,271
Indonesia	0 ^a	540	414	21 (21)	7,704	839	ND	ND
Maldives	0	0	0	0 (0)	0	0	0	0
Myanmar	0	29	ND	14 (14)	10	0	ND	6
Nepal	0	95	4,828	768 (3)	130	24	8,898	79
Sri Lanka	0	0	0	5 (0)	0	0	73	16
Thailand	0	0	10	0 (0)	250	9	549	0
Timor-Leste	0	0	0	2 (1)	8	41	0	1
SEAR	0	3,956	9,614	896 (125)	51,911	3,714	9,526	1,483

Country	2023							
	Polio	Diphtheria	Pertussis	Total tetanus (NT)	Measles	Rubella	Mumps	JE
Bangladesh	0	9	0	35 (35)	280	182	ND	31
Bhutan	0	0	0	0 (0)	10	4	0	0
DPR Korea	0	0	0	0 (0)	0	0	ND	0
India	0	3,850	4,949	62 (62)	65,546	2,922	195	1,320
Indonesia	0 ^b	956	2,163	2,510 (27)	18,063	584	ND	12
Maldives	0	0	0	0 (0)	5	0	0	0
Myanmar	0	90	50	8 (8)	15	2	ND	19
Nepal	0	27	4,206	0 (0)	963	34	28,984	105
Sri Lanka	0	0	3	6 (0)	810	0	103	6
Thailand	0	47	1,198	0 (0)	677	12	646	0
Timor-Leste	0	0	0	0 (0)	7	3	0	0
SEAR	0	4,979	12,569	2,621 (132)	86,376	3,743	29,928	1,493

Source: WHO/UNICEF JRF (2021-2023)


^aExcludes one type 2 VDPV

^bExcludes six type 2 and one type 1 VDPV

ND = No data




DTP3 coverage by country, 2021-2023




Source: WHO and UNICEF estimates of immunization coverage

Percentage districts achieving ≥80% DTP3 coverage by country, 2021-2023



Source: WHO UNICEF JRF (Multiple years)


Drop-out rates by country, 2021-2023




Source: WHO and UNICEF estimates of immunization coverage

Measles and rubella elimination

Status of measles and rubella elimination




Measles cases and coverage of measles containing vaccine 1st and 2nd dose (MCV1; MCV2), 2000-2023



Source: WHO UNICEF coverage estimates, WHO UNICEF JRF and EPI/MoHFW; Measles cases from JRF 2000-2023


Rubella cases and rubella containing vaccine (RCV) coverage, 2005-2023



Source: WHO UNICEF coverage estimates, WHO UNICEF JRF and EPI/MoHFW; Rubella cases from JRF 2005-2023




MCV1 coverage by country, 2021-2023




Source: WHO and UNICEF estimates of immunization coverage

MCV2 coverage by country, 2021-2023




Source: WHO and UNICEF estimates of immunization coverage

Percent districts with MCV1 coverage by country, 2023




Source: WHO UNICEF JRF, 2023

Percent districts with MCV2 coverage by country, 2023




Source: WHO UNICEF JRF, 2023

MCV1 immunization coverage by first administrative level*, 2023



MCV2 immunization coverage by first administrative level*, 2023



Measles and rubella surveillance performance indicators, 2023

Country	No. of suspected measles cases	Case classification (number)						Indicators				
		Measles			Rubella		Discarded non-measles non-rubella cases	Annual incidence of confirmed measles cases per million total population	Annual incidence of confirmed rubella cases per million total population	Proportion of all suspected measles and rubella cases that have had an adequate investigation initiated within 48 hours of notification	Non-measles non-rubella discard rate per 100 000 total population	Proportion of surveillance units reporting on time
		Lab-confirmed	Epi-linked	Clinically-confirmed	Lab-confirmed	Epi-linked						
Bangladesh	7,346	237	42	1	126	56	6,882	1.60	1.04	97%	3.92	98%
Bhutan	232	4	0	0	6	0	219	5.19	6.49	94%	28.43	ND
DPR Korea	512	0	0	0	0	0	512	0.00	0.00	100%	2.07	ND
India	154,417	36,959	22,197	6,390	2,826	96	82,692	45.69	2.04	96%	5.75	93%
Indonesia	39,890	10,628	441	6,994	584	0	13,450	63.14	2.08	91%	4.85	91%
Maldives	177	5	0	0	0	0	171	8.47	0.00	73%	28.97	ND
Myanmar	180	9	0	6	2	0	163	0.27	0.04	100%	0.30	33%
Nepal	3,030	239	713	11	34	0	2,031	32.90	1.16	99%	6.94	ND
Sri Lanka	1,217	803	0	0	0	0	377	36.20	0.00	93%	1.70	ND
Thailand	677	26	1	37	12	0	601	0.57	0.15	98%	0.91	81%
Timor-Leste	202	10	0	0	6	0	193	7.48	4.49	100%	13.99	ND

Source: MR surveillance database

ND = no data


Measles and rubella laboratory surveillance indicators, 2023

Country	Serum specimen collected from suspected measles cases		Specimens received at the laboratory within 5 days of collection		Specimen positive for measles IgM		Specimen positive for rubella IgM		Results reported by the laboratory within 4 days of receiving the specimen for serology	Genotypes detected	
	No.	%	No.	%	No.	%	No.	%	%	Measles	Rubella
Bangladesh	6,532	89%	6,481	99%	238	4%	126	2%	98%	-	-
Bhutan	437	100%	245	56%	10	2%	5	1%	100%	-	-
DPR Korea	510	100%	510	100%	0	0%	0	0%	100%	-	-
India	118,318	77%	98,758	83%	34,624	29%	2,546	2%	64%	B3, D8	-
Indonesia	33,567	86%	20,564	61%	13,134	39%	773	2%	48%	B3, D8	-
Maldives	173	98%	173	100%	4	2%	4	2%	100%	-	-
Myanmar	179	99%	157	88%	9	5%	2	1%	100%	-	-
Nepal	2,469	81%	2,456	99%	224	9%	47	2%	76%	D8	-
Sri Lanka	1,222	100%	1,160	95%	498	41%	0	0.0%	88%	D8	-
Thailand	ND	ND	ND	ND	ND	ND	ND	ND	ND	-	-
Timor Leste	188	93%	154	82%	7	4%	4	2%	36%	-	-


Source: SEA Region annual EPI reporting form, 2023

ND = no data

Rubella vaccine introduction through routine immunization program




Immunity profile against measles through vaccination, 2023*



*Modelled using MSP tool ver 2

Immunity against rubella through vaccination - immunity profile by age in 2023*



*Modelled using WHO and UNICEF estimates and JRF (multiple years) and does not include immunity due to natural infection




Maintaining polio-free status

Polio-free certification status maintained since 2014

Last wild poliovirus (WPV) cases by type



DPR Korea




Last wild poliovirus case by country	
Country	Year
Bangladesh	2006
Bhutan	1986
DPR Korea	1996
India	2011
Indonesia	2006
Maldives	1994
Myanmar	2007
Nepal	2010
Sri Lanka	1993
Thailand	1997
Timor-Leste	1995

Immunization coverage with 3rd dose of oral polio vaccine (OPV3) and inactivated polio vaccine (IPV), 2019-2023

Country	OPV3					IPV1				
	2019	2020	2021	2022	2023	2019	2020	2021	2022	2023
Bangladesh	98	98	98	98	98	92	96	96	97	98
Bhutan	97	96	98	98	98	96	93	98	99	96
DPR Korea	98	70	0	0	0	98	98	99	99	0
India	90	85	85	93	91	82	81	82	91	90
Indonesia	85	76	68	91	82	76	37	61	77	71
Maldives	99	99	97	99	99	98	99	96	99	99
Myanmar	90	86	43	75	80	90	86	46	71	78
Nepal	92	84	91	87	93	80	73	86	84	75
Sri Lanka	99	96	96	98	99	99	96	96	98	99
Thailand	97	97	93	93	93	97	97	92	92	92
Timor-Leste	83	83	83	83	83	81	80	80	80	80
SEA Region	90	85	82	92	89	83	77	80	89	87

Source: WHO and UNICEF estimates of immunization coverage

IPV immunization coverage by first administrative level*, 2023



* Bhutan, Maldives and Timor-Leste by country

Source: SEA Region annual EPI reporting form, 2023

Acute flaccid paralysis (AFP) surveillance indicators by country, 2021-2023


Country	2021					2022					2023				
	AFP	WPV confirmed cases	VDPV cases	Non-polio AFP rate ^a	Adequate stool specimen collection percentage ^b	AFP	WPV confirmed cases	VDPV cases	Non-polio AFP rate ^a	Adequate stool specimen collection percentage ^b	AFP	WPV confirmed cases	VDPV cases	Non-polio AFP rate ^a	Adequate stool specimen collection percentage ^b
Bangladesh	1,235	0	0	2.54	99	1,264	0	0	2.63	99	1,486	0	0	3.08	99
Bhutan	2	0	0	1.01	50	3	0	0	1.67	67	6	0	0	3.35	83
DPR Korea	134	0	0	1.90	100	132	0	0	2.30	100	129	0	0	2.25	100
India	25,424	0	0	5.60	86	30,207	0	1	6.65	88	27,741	0	0	6.03	89
Indonesia	1,050	0	0	1.52	70	2,414	0	1	3.65	77	4,345	0	7	6.59	83
Maldives	2	0	0	2.10	100	10	0	0	8.89	30	14	0	0	7.08	43
Myanmar	33	0	0	0.23	85	150	0	0	1.10	89	265	0	0	2.01	94
Nepal	260	0	0	3.00	99	219	0	0	2.71	97	207	0	0	2.64	93
Sri Lanka	69	0	0	1.06	78	86	0	0	1.52	71	98	0	0	1.73	73
Thailand	75	0	0	0.47	68	96	0	0	0.59	60	177	0	0	1.41	70
Timor-Leste	0	0	0	0.00	0	2	0	0	0.42	50	2	0	0	0.42	0
SEAR	28,321	0	0	4.54	86	34,584	0	2	5.64	88	34,470	0	7	5.56	89

^a Number of discarded AFP cases per 100 000 children under 15 years of age

^b Percentage with 2 specimens, 24 hours apart and within 14 days of paralysis onset


AFP surveillance indicators by first administrative level*, 2023

Non-polio AFP rate¹



* Bhutan, Maldives and Timor-Leste by country
¹ Number of discarded AFP cases per 100 000 children under 15 years of age

Percentage adequate stool specimen collection²



* Bhutan, Maldives and Timor-Leste by country
² Percentage with 2 specimens 24 hours apart and within 14 days of paralysis onset

Environmental surveillance for poliovirus detection, 2021 - 2023

Country	2021					2022					2023				
	Number of sites	Number of samples collected	# WPVs detected	# VDPVs detected	NPEV	Number of sites	Number of samples collected	# WPVs detected	# VDPVs detected	NPEV	Number of sites	Number of samples collected	# WPVs detected	# VDPVs detected	NPEV
Bangladesh	8	120	0	0	67	8	148	0	0	98	14	208	0	0	114
India	58	1,533	0	0	683	63	1,739	0	1	803	63	1,847	0	0	1,010
Indonesia	13	144	0	0	19	13	155	0	0	51	15	136	0	1	55
Myanmar	3	25	0	0	11	1	12	0	0	6	3	34	0	0	10
Nepal	5	125	0	0	50	7	115	0	0	52	7	128	0	0	40
Thailand	6	136	0	0	43	6	154	0	0	21	11	162	0	0	45
SEAR	93	2,083	0	0	873	98	2,323	0	1	1,031	113	2,515	0	1	1,274

Note: Environmental surveillance started-India in 2002, Bangladesh in 2015, Indonesia and Thailand in 2016, Myanmar and Nepal in 2017

WPV: Wild Polio Virus; VDPV: Vaccine Derived Polio Virus; NPEV: Non Polio Enterovirus

National immunization days (NIDs)/Sub-national immunization days (SNIDs) by country


Country	Year of 1st NID	Total NIDs conducted	Most recent NID	SNIDs in 2023
Bangladesh	1995	40	Jan-14	No
Bhutan	1995	2	Nov-95	No
DPR Korea	1997	12	Nov-02	No
India	1995	46	Feb-22	Yes
Indonesia	1995	14	Mar-16	Yes
Maldives	1996	8	Jan-01	No
Myanmar	1996	23	Feb-16	Yes
Nepal	1996	27	Jan-14	No
Sri Lanka	1995	8	Dec-00	No
Thailand	1994	10	Jan-00	Yes
Timor-Leste	1995*	12	Feb-23	No

* SIA conducted while still part of Indonesia


Elimination of maternal and neonatal tetanus (MNT) is sustained

Maternal and neonatal tetanus elimination achieved and maintained since 2016.

MNT elimination timeline




Immunization coverage with 2 or more doses tetanus toxoid (TT2+), 2021-2023



Source: This data is based on official and administrative system as reported in the Joint Reporting Form WHO UNICEF JRF (multiple years)


TT2+ coverage and neonatal tetanus cases, 2000-2023




Source: TT2+ coverage refers to country official estimates, neonatal tetanus cases from JRF 2000-2023

Control of Japanese encephalitis (JE) is accelerated

JE vaccine introduction status




JE final dose immunization coverage by first administrative level, 2023



Source: SEA Region annual EPI reporting form, 2023

Control of hepatitis B is accelerated

Hepatitis B control status




Immunization coverage of 3rd dose hepatitis B vaccine (HepB3) and HepB birth dose by country, 2019-2023

Country	HepB3					HepB birth dose				
	2019	2020	2021	2022	2023	2019	2020	2021	2022	2023
Bangladesh	98	98	98	98	98	no birth dose				
Bhutan	97	96	98	98	99	86	85	84	94	94
DPR Korea	97	97	41	0	16	98	99	99	50	0
India	91	85	85	93	91	56	54	55	63	63
Indonesia	85	77	67	91	83	84	73	70	85	88
Maldives	98	99	96	99	99	99	99	99	99	99
Myanmar	90	84	37	71	76	17	21	6	8	17
Nepal	93	84	91	90	94	no birth dose				
Sri Lanka	99	96	96	98	99	no birth dose				
Thailand	97	97	92	92	92	96	93	89	89	89
Timor-Leste	83	83	83	83	83	62	64	76	76	76
SEAR	91	86	83	92	90	53	50	50	57	57

Source: WHO and UNICEF estimates of immunization coverage


HepB birth dose coverage by first administrative level*, 2023




* Bhutan, Maldives and Timor-Leste by country
Source: SEA Region annual EPI reporting form, 2023

Introduction of new vaccines and related technologies is accelerated


HPV introduction status




RV vaccine introduction status




RV final dose immunization coverage by first administrative level*, 2023




Pneumococcal conjugate vaccine (PCV) introduction status



Seasonal influenza vaccine (SIV) introduction status



Typhoid containing vaccine (TCV) introduction status



Access to high-quality vaccine is ensured


Vaccine safety by country


Country	Activities being implemented		Adverse events following immunization (AEFI)		
	Immunization injection safety	Vaccine adverse events review committee	National system to monitor AEFI	No. AEFI Reported	Of the total adverse events reported No of serious
Bangladesh	Yes	Yes	Yes	1,760	32
Bhutan	Yes	Yes	Yes	0	0
DPR Korea	Yes	Yes	Yes	25	6
India	Yes	Yes	Yes	3,200	3,200
Indonesia	Yes	Yes	Yes	16,434	30
Maldives	Yes	Yes	Yes	14	0
Myanmar	Yes	Yes	Yes	20,713	21
Nepal	Yes	Yes	Yes	17	17
Sri Lanka ¹	Yes	Yes	Yes	8,506	834
Thailand	Yes	Yes	Yes	343	89
Timor-Leste	Yes	Yes	Yes	42	38

Source: WHO/UNICEF JRF, 2023 and SEAR annual EPI reporting form 2023
¹ Adverse Events Following Immunization; Sri Lanka AEFI data do not reflect cases but events.

Laboratory network for vaccine preventable diseases

Polio laboratory network






Country	National laboratory	Sub-national laboratory	Regional reference laboratory	Total
Bangladesh	1			1
Bhutan	1			1
DPR Korea	1			1
India	7	18	2	27
Indonesia	3	4		7
Maldives	1			1
Myanmar	1	1		2
Nepal	1	1		2
Srilanka	1			1
Thailand		13	1	14
Timor-Leste	1			1
Total	18	37	3	58

JE/AES, rota and invasive bacterial disease (IBD) laboratory network



DPR Korea



Country	JE/AES national laboratory	JE/AES reference laboratory	GPDS national laboratory	Rota national laboratory	GPDS/Rota reference laboratory	IBD national laboratory	IBD reference laboratory
Bangladesh	1			1		1	
Bhutan	1			1		1	
DPR Korea	1		1	1		1	
India	5	1	1	1	1	1	1
Indonesia*	1			1			
Maldives				1			
Myanmar*	2		1	1			
Nepal*	2			1		1	
Sri Lanka	1					1	
Thailand	1			1		1	
Timor-Leste	1			1			
Total	16	1	3	10	1	7	1

* Country reports to Global surveillance network (GRSN)

For contact or feedback:

Immunization and Vaccine Development (IVD), Department of Communicable Diseases

World Health Organization, Regional Office for South East Asia, IP Estate,
Mahatma Gandhi Marg, New Delhi 110002, India

Tel: +91 11 23370804, Fax: +91 11 23370251 | Email: SearEpidata@who.int
www.searo.who.int/entity/immunization



REGIONAL OFFICE FOR

World Health Organization
South-East Asia



Immunization: Leaving no one behind